1826 ET - As Hims & Hers Health continues to revamp its offerings to focus on personalization, it's turning its attention toward its sexual health specialty, where most subscribers have historically favored "on-demand" solutions, the company said in a letter to shareholders. Such treatments limit personalized benefits, so Hims has looked to focus on users who would benefit from a more precise daily solution. The transition has slowed customer acquisition within the segment, but subscriber and revenue growth outside of the company's popular GLP-1 weight loss drugs were still nearly 30% in 1Q. "Our approach is to align our investments toward long-term value creation, even if that results in temporary near-term headwinds for the business," the company said. (kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
May 05, 2025 18:27 ET (22:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.